Abstract
INTRODUCTION
Gastric cancer (GC) is a frequently occurring malignancy of the digestive tract [1] , and it was the fifth most commonly diagnosed and the third most common cause of cancerrelated mortality worldwide in 2018 [2] . Lack of early diagnosis and ineffective treatment options for the advanced stages are the primary reasons for the dismal 5-year survival rate of GC [3] . Therefore, it is imperative to identify novel biomarkers for early diagnosis and accurate prediction of prognosis. Vestigial like family member 3 (VGLL3) is a member of the vestigial like family of proteins [4] , and is associated with epithelial ovarian cancer [5] and soft tissue sarcoma [6] . The aim of this study was to determine the expression status and prognostic utility of VGL33 in GC. To this end, we mined the transcriptomic data of GC from the ONCOMINE and GEPIA databases, and determined its correlation with the survival data from GEPIA and ONCOLINC. VGLL3 levels were upregulated in GC samples and associated with a poor prognosis. The bioinformatics data were successfully validated on the tumor and normal gastric tissues resected from GC patients. Based on the VGLL3 levels, the patients were stratified into the high and low expression groups, and a prognosis prediction model was established on the basis of VGLL3 status and clinical data. Our findings show a strong prognostic role of VGLL3 in GC, which can potentially translate to clinical applications.
MATERIALS AND METHODS

Patients and tissue samples
A total of 172 tissue samples were obtained from gastric adenocarcinoma patients who underwent major surgery at the Affiliated Hospital of Jiangnan University between 2009 and 2012. The tissues were immediately fixed in formalin and embedded in paraffin for further analysis. In addition, fresh samples were dissected from 30 patients at the Affiliated Hospital of Jiangnan University in November 2018, and immediately stored in liquid nitrogen for molecular analysis. The mean follow-up duration was 43.1 mo and ranged from 0.2 to 86 mo. None of the patients received chemotherapy or radiotherapy before surgery [7] . The tumor stage classification was determined by three pathologists who were blinded to the patient data according to the guidelines of the American Joint Committee on Cancer (AJCC). Freshly resected tissues were obtained from 202 patients, and were fixed in formalin and embedded in paraffin. In addition, tissue specimens from 30 patients were flash frozen in liquid nitrogen. All participating clinicians and patients provided written informed consent.
Bioinformatics analysis
The VGLL3 mRNA levels in the GC and normal gastric tissues were determined by integrated analysis of the Oncomine database (www.oncomine.org) [8] using Coexpedia (www.coexpedia.org) [9] . ONCOLINC (http://www.oncolnc.org/cancer/) and Coexpedia were used to analyze the prognostic value of WISP1 in STAD. The STRING database (http://www.string-db.org) was utilized to construct the proteinprotein interaction (PPI) network [10] .
RNA isolation and RT-qPCR
Total RNA was extracted from frozen tissue samples using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and reverse transcribed using the PrimeScript RT-PCR kit (Takara, Japan) [11] . RT-qPCR was performed on the ABI 7500 RealTime PCR System (Applied Biosystems, Inc. USA) using SYBR Green Master Mix (Takara, Japan), and the VGLL3 levels were normalized to β-actin. The following primers were used: Forward primer, 5'-CCAACTACAGTCACC-TCTGCTAC-3' and reverse primer, 5'-ACCACGGTGATTCCTTACTCTTG-3' for VGLL3; forward primer, 5'-CCTGTGGCATCCACGAAACT-3' and reverse primer, 5'-GAAGCATTTGCG GTGGACGAT-3' for β-actin. All reactions were performed in triplicates, and the 2 -∆∆Ct method [12] was used to quantify the relative expression levels of VGLL3.
Western blot analysis
Total protein was extracted from GC and para-cancerous tissues using the RIPA lysis buffer (Pierce, Thermo Scientifc, Cramlington, United Kingdom) [13] , and quantified with the enhanced BCA protein assay kit (KeyGEN BioTECH, Jiangsu, China). Equal amount (40 mg) of proteins per sample were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SD-PAGE), and then transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, United States). After blocking with 5% non-fat milk for 1 h at room temperature (RT), the membranes were incubated overnight with anti-VGLL3 (ab83555, Abcam) and β-actin (ab8226, Abcam) primary antibodies at 4 °C. After washing thrice with TBST, the membranes were incubated with HRP-conjugated secondary antibody (1:1000) for 1 h at RT. The protein bands were visualized with an ECL chemiluminescence system after short exposure to X-ray films (Kodak, Japan). Densitometric analysis was performed with Image Pro-Plus software, and the relative expression levels of VGLL3 were normalized to tubulin.
Immunohistochemistry (IHC)
The formalin-fixed tissues were dehydrated, embedded in paraffin, and cut into 5 μm thick sections. IHC was performed according to the manufacturer's protocol [14] . Briefly, the sections were heated in citrate buffer in a microwave, cooled, and incubated overnight with anti-VGLL3 antibody (1:50, clone PA5-68441, Invitrogen) at 4 °C. After labeling with the secondary antibody for 1 hour at RT, color was developed using liquid DAB substrate. Three pathologists blinded to the patient identity observed and graded VGLL3 positivity as 0, 1 (1%-29% positively-stained cells), 2 (30%-69%), or 3 (70%-100%), and the staining intensity as 0 (negative), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The immunoreactive score (IRS) was then calculated for each sample by multiplying the staining intensity and positivity scores, and graded as: 0-1, "-"; 2-3, "+"; 4-6, "++"; and 6-9, "+++" [15] . Based on the IRS, the samples were stratified into the high (4-9) and low (0-3) VGLL3 expression groups.
Fluorescence in situ hybridization (FISH)
The tissue sections were treated with denaturing solution to denature the DNA into single strands, and hybridized with the PathVysion probes (No.36-161060, PathVysion HER-2DNA Probe Kit). After washing the unbound probe with DNA, the sections were counterstained with the nuclear dye DAPI (4', 6 diamidino-2-phenylindole). Positive LSI HER-2/neu and CEP 17 signals were counted under a fluorescence microscope, and the ratio of the copy number of HER-2/neu gene to that of chromosome 17 was calculated.
Statistical analysis
Statistical analyses were performed with R*64 version 3.5.2 software and Graphpad 6.01. HER2 status (positive or negative) was designated on the basis of the combined FISH and IHC results as per the American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guidelines. VGLL3 expression levels in the tumor and normal samples were compared by the Student's t-test, and the association between VGLL3 and clinico-pathological features was assessed by the chi-square test. The overall survival (OS) curve was plotted by the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses of the prognostic factors were performed using the Cox proportional hazard regression model. A nomogram was formulated based on the results of the multivariate analysis with the package of rms in R version 3.5.2 (http://www.r-project.org/) [16] . The receiver operating characteristic (ROC) curve was plotted to determine the sensitivity and specificity of the VGLL3-based prognostic score [17] , and the area under the curve (AUC) was calculated. All P-values were two-tailed and considered statistically significant when less than 0.05.
RESULTS
VGLL3 mRNA and protein levels are upregulated in GC samples
GEPIA database profiling showed that although VGLL3 was significantly overexpressed in GC samples of advanced TNM stages relative to those at the lower stages (P = 0.0163), there was no significant difference between the GC and normal tissues (P > 0.05). Integrated analysis of multiple VGLL3 transcriptome datasets from the ONCOMINE database, however, showed that VGLL3 was significantly overexpressed in GC (P = 0.003), and notably associated with a poor prognosis according to the ONCOLINC database analysis (P = 0.01, n = 378) (Figure 1 ). In addition, GEPIA online survival analysis further confirmed that VGLL3 was a marker of poor prognosis in GC (P = 0.0062, n = 384). To validate the in silico data, we analyzed the expression levels of VGLL3 in the tumor and normal gastric tissues resected from 30 GC patients, and observed significantly higher levels of VGLL3 mRNA (P < 0.001) and protein (P < 0.001) in the GC tissues compared to normal tissues ( Figure 2 ). Taken together, VGLL3 is upregulated in GC and possibly associated with a worse prognosis.
VGLL3 is a potential prognostic factor for GC
The relationships between VGLL3 levels and the clinico-pathological characteristics of the patients are summarized in Table 1 . High levels of VGLL3 were positively correlated with tumor lymph node metastasis (P = 0.028) and TNM stage (P = 0.041). In addition, the median survival time of the GC patients was significantly lower in the high VGLL3 expression group than in the low expression group (35 mo vs 49 mo, P = 0.019; Figure 3C ). Univariate analysis showed that the VGLL3 expression level (P = 0.019) was the only significant prognostic factor of GC, whereas age, gender, differentiation, T stage, lymph node status, TNM stage, and HER2 status did not show any significant results (P > 0.05). After including the significant factors in the Cox proportional hazards regression model for multivariate prognostic analysis, we found that VGLL3 expression (P = 0.019) was an independent risk factor for GC. ROC curves were plotted to determine the power of the VGLL3 prognostic score in predicting the 3-and 5-year survival, and the AUCs were 0.613 and 0.706, respectively ( Figure 3I ). We constructed a PPI network of VGLL3 using the STRING database, and identified YAP1, TEAD1, WWTR1, and VGLL4 as upstream of VGLL3, and POU1F1, TEAD3, AKAP11, SYT17, CHMP28, TEAD4, and ERBBE2 (HER2) as downstream proteins (Table 2 ). 
DISCUSSION
GC is the third most common cause of cancer-related deaths worldwide, mainly due to ineffective diagnostic and therapeutic options. It is often detected at the advanced stage, and is highly heterogeneous. Therefore, novel molecular biomarkers for the early diagnosis and treatment of GC are urgently needed. VGLL3 is a member of the vestigial-like family proteins that are related to sex and maturation [18] [19] [20] , and is reportedly associated with epithelial ovarian cancer and soft tissue sarcoma. Through bioinformatics data mining and integrated analysis, we found that VGLL3 mRNA was not only upregulated in the GC tissues relative to normal gastric tissues, but also significantly associated with advanced TNM stage GC and poor survival outcomes.
To validate the in silico data, we analyzed the gastric tissues of GC patients, and found abnormally high levels of VGLL3 in the tumor relative to normal tissues. In addition, high in situ expression of VGLL3 was correlated with tumor lymph node metastasis, TNM stage, and HER2 mutation, but not with age, gender, differentiation, T stage, or M stage. The patients were stratified into the high and low VGLL3 expression groups, and the former showed a significantly poor survival. Univariate and multivariate analyses further indicated that VGLL3 expression and TNM stage were independent risk factors for the prognosis of GC. Finally, the respective AUCs of the 3-and 5-year survival of the VGLL3-based prognostic model were 0.613 and 0.706, indicating a somewhat imperfect predictive ability. This could be due to the insufficient number of samples and other confounding factors such as the patient's state of mind, economic status, and family environment. Taken together, we identified VGLL3 as a novel prognostic biomarker for GC.
To further elucidate the underlying molecular mechanisms, we analyzed the PPI network of VGLL3 through the STRING database, and found that the Hippo pathway was significantly enriched. In addition, the identified upstream molecules of VGLL3 are YAP1 [6] , TEAD1, WWTR1, VGLL4, and the downstream molecules are POU1F1, TEAD3, AKAP11, SYT17, CHMP28, and TEAD4. Interestingly, the expression level of VGLL3 was related to ERBBE2 (HER2) mutation, although the relevant mechanistic connection is unclear.
To conclude, VGLL3 is highly expressed in GC and an independent risk factor, and further studies are needed to determine its underlying mechanism. Nevertheless, VGLL3 is a novel biomarker for GC prognosis and a potential therapeutic target for this malignancy. 
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VGLL3 is overexpressed in GC tissues and associated with a poor prognosis, indicating its potential as a novel prognosis biomarker and therapeutic target for GC.
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The present study suggested that VGLL3 is a novel prognostic biomarker for GC, and the significance of VGLL3 as a promising therapeutic target for GC is highlighted.
